What is FBIOP's market cap?

$56.62M, based on the Sep 28 close of $16.52.

What is FBIOP's P/E ratio?

0.5× trailing-twelve-month earnings of $103.37M.

What sector is FBIOP in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · FBIOPHealthcarePharmaceuticals

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP)

$16.52−0.75%

Close Sep 28, 2026 · split-adjusted

Sep 28, 2026$16.52▲ 80.55% in range

Sep 29, 2025Low $6.53 · High $21.08Sep 28, 2026

What changed · written from our data

As of Sep 28, 2026

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock closed at $16.52 on Sep 28, down 0.75%, 21.6% below its 52-week closing high. Volume of 10.4K shares was 1.01× its 20-day average (close to normal).

Split-adjusted performance: -11.0% over one month, +23.5% over six months, +81.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $18.72M, up 14.0% from a year earlier, with a net margin of -13.2%.

Short interest was 848 shares at the Aug 31 settlement, up 19.4% from the prior report (1.0 days to cover).

Market cap$56.6M3.4M shares

Revenue · quarter$18.7M+14.0% YoY

Diluted EPS$-0.08−117.8% YoY

P/E · TTM0.5×P/S 0.8×

Net margin-13.2%Gross 67.2%

Dividend yieldNone$0.1953 last paid

52-week range6.53 – 21.08−21.6% from high

Volume10.4K1.01× 20-day avg

Volatility · 60d19.2%Annualised

Short % of float—1.0 days to cover

Net cash$157.0MCash $196.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −4.3%1M −11.0%3M −17.7%6M +23.5%YTD +74.1%1Y +81.3%3Y +40.1%5Y −35.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 423 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −2.9%, revenue growth +6.4%, net margin −42.6%, P/E 16.2×.

Short interest

Details →

Shares short848+19.4% vs prior

Days to cover1.0Settled Aug 31

% of float—

Short vol. 10d26.1%of daily volume

News about Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

All news →

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswire Inc. · Sep 8, 2026▲ Positive

Quick answers

What does Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock do?: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products.
What is FBIOP's market cap?: $56.62M, based on the Sep 28 close of $16.52.
What is FBIOP's P/E ratio?: 0.5× trailing-twelve-month earnings of $103.37M.
What sector is FBIOP in?: Healthcare, in the Pharmaceuticals industry.

About Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

HQ: Bay Harbor Islands, FL78 employeesListed Nov 14, 2017fortressbiotech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology